So the enrollment for the 342 severely ill patients is a double blinded study. They never mentioned placebo. So at a 2:1 ratio, does this mean that 228 patients will be injected with Leronlimab and 114 with a placebo? Why a placebo when these are patients with severe symptoms and could die during the trial?